The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
ID: ALA3785321
Max Phase: Preclinical
Molecular Formula: C20H14Cl2N2O3
Molecular Weight: 401.25
Molecule Type: Small molecule
Associated Items:
Representations Canonical SMILES: Cc1ccoc1C(=O)Nc1ccc(N2Cc3c(Cl)cccc3C2=O)c(Cl)c1
Standard InChI: InChI=1S/C20H14Cl2N2O3/c1-11-7-8-27-18(11)19(25)23-12-5-6-17(16(22)9-12)24-10-14-13(20(24)26)3-2-4-15(14)21/h2-9H,10H2,1H3,(H,23,25)
Standard InChI Key: FVHRTMALRHTFIM-UHFFFAOYSA-N
Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Properties Molecular Weight: 401.25Molecular Weight (Monoisotopic): 400.0381AlogP: 5.31#Rotatable Bonds: 3Polar Surface Area: 62.55Molecular Species: NEUTRALHBA: 3HBD: 1#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 1CX Acidic pKa: 12.56CX Basic pKa: CX LogP: 4.55CX LogD: 4.55Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.65Np Likeness Score: -1.24
References 1. Garcia-Barrantes PM, Cho HP, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW.. (2016) Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs., 26 (8): [PMID:26988302 ] [10.1016/j.bmcl.2016.03.031 ]